SEC Filing Summary: Immudyne, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Immudyne, Inc. on September 21, 2017. The report details a corporate governance action regarding the company's capital structure. Note: The request metadata references "Lifemd, Inc.," but the filing text explicitly identifies the registrant as "Immudyne, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a corporate amendment and does not contain financial performance data.
Material Changes
On September 21, 2017, Immudyne, Inc. amended its certificate of incorporation filed with the Delaware Secretary of State. The primary material change is the increase in the number of authorized shares of common stock:
- Previous Authorized Shares: 50,000,000
- New Authorized Shares: 100,000,000
The amendment was approved by the Board of Directors and by holders of a majority of outstanding common shares via written consent.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future performance, specific risks, or contingencies related to financial operations. The document focuses solely on the procedural execution of the share authorization increase.
Investor Verification Checklist
- Verify the exact number of outstanding shares versus the new authorized limit of 100,000,000 to assess potential dilution.
- Confirm the date of the written consent from shareholders approving the amendment.
- Review the attached Exhibit 3.1 (Certificate of Amendment) for any additional provisions or restrictions not summarized in the main text.
- Clarify the discrepancy between the request metadata (Lifemd, Inc.) and the filing registrant (Immudyne, Inc.).